What Does Fresenius SE & Co. KGaA Do?
Fresenius SE & Co. KGaA, trading under the ticker FRE.DE, is a major player in the healthcare sector, specifically within the medical care facilities industry. The company provides a wide range of healthcare services, including hospital management, outpatient care, and dialysis treatment. With a substantial market presence in healthcare, Fresenius reported revenue of approximately €22.87 billion, underscoring its significant footprint in the industry.
The Buffett-Framework Verdict
Applying the Buffett framework, Fresenius scores a "D" with a total score of 36. This verdict suggests that the company lacks a durable economic moat and has weak profitability metrics. Here are some of the key points:
- Moat: Fresenius scores 12, indicating a lack of competitive advantage.
- Durability: A score of 10 raises concerns about the company's long-term viability.
- Management: With a score of 64, Fresenius shows competent management, which is a positive factor.
- Valuation: Fresenius scores 64 in valuation, suggesting it might be fairly valued.
- Financial Health: A score of 37 indicates room for improvement.
For a detailed Buffett-style analysis, visit the Buffett verdict on FRE.DE.
Valuation and Margin of Safety
Fresenius is currently trading at €45.04 with a P/E ratio of 16.16. While this suggests a reasonable valuation compared to the broader market, the company’s financial metrics reveal some weaknesses. The return on invested capital (ROIC) stands at 5.9%, which is below the sector's top-quintile cutoff of 10.7%. The net margin is 5.5%, also below the sector standard of 12.7%. These figures indicate limited profitability, which can pose a risk to investors.
The Bull Case
- Market Presence: Fresenius's substantial revenue base of €22.87 billion highlights its strong market presence.
- Cash Flow: The company generates free cash flow of €1.08 billion, indicating an ability to generate cash, which is crucial for operations and potential expansion.
- Interest Coverage: With an interest coverage ratio of 5.9, Fresenius comfortably meets its interest obligations, reducing financial risk.
The Bear Case
- Profitability Concerns: The gross margin of 24.9% and a declining EPS CAGR of -2.81% highlight ongoing profitability issues.
- Historical Profitability: Fresenius was not profitable in at least one of the last five years, raising red flags about its financial stability.
- Competitive Pressure: The company’s low moat score indicates vulnerability to competitive pressures, which may impact its market share and pricing power.
The Bottom Line
Fresenius SE & Co. KGaA presents a mixed investment case. While it benefits from a strong market presence and solid cash flow generation, its profitability metrics and competitive positioning raise concerns. Investors should weigh these factors carefully and consider their own risk tolerance before making an investment decision.
For more details on Fresenius's financials and performance, check out the stock page for FRE.DE.
This is educational, not financial advice.